Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

By S. Altekruse, K. McGlynn, M. Reichman. Journal of Clinical Oncology, 2009

1,736 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. (2012, neutral): “Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the third leading cause of cancer-related death (6, 7).”
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study (2015, background): “Although the incidence of HCC has historically been low in North America and Europe, there is evidence for a significant upward trend in the United States in recent years (6, 7), which has been attributed to an increased prevalence of HCV infection (8).”
Hepatocellular carcinoma: a global view (2010, neutral): “nrgastro; and (4) view/print certificate.”
Global Cancer in Women: Burden and Trends (2017, background): “The increases in the United States are thought to be due to increased prevalence of chronic HCV infection due to exposure to contaminated blood products or medical devices and injection drug abuse during the 1960s and 1970s (165).”